AML Hub

🎥 During the recent AML Hub Steering Committee meeting, Jorge Sierra chaired a discussion on personalizing AML care with FLT3 inhibitor therapy. Watch the video here: bit.ly/4sKeLHv #AMLsm #leusm #MedEd @charliecraddock @jorgecortesmd @LancetJeff @UwePlatzbecker @RolandBWalter Intended for healthcare professionals only. This educational resource is independently supported by Daiichi Sankyo. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.

🚨News 🚨 @US_FDA approves decitabine/cedazuridine + venetoclax for patients with ND AML who are unfit for intensive chemotherapy, based on results from the phase II ASCERTAIN-V study. Read more: bit.ly/4wBMgzc #AMLsm #leusm #MedEd #MedNews

New publication 📝 Results from the real-world PETHEMA study, published in @AJHematology, show FLAG-Ida achieved 56.8% CRc in patients with R/R AML, bridging 35.2% of patients to allo-HSCT. Learn more about AML: bit.ly/4cEaOym #AML #leusm #MedNews #MedEd

🔍 Looking for trusted, in-depth #AcuteMyeloidLeukemia education? The AML Hub's educational resource center has you covered. Browse a wealth of content all in one place. bit.ly/41X6Mft   #amlsm #MedEd #leusm

🎥 In our latest expert masterclass, Eunice Wang, Gail Roboz, and Joshua Zeidner discuss the rationale, side effects, and emerging clinical trial data for menin inhibitor combination strategies for the treatment of AML. Watch the videos here: aml-hub.com/medical-inform… #AMLsm #leusm #MedEd @EuniceWangMD @LeukDocJZ Intended for healthcare professionals only. This educational resource is independently supported by Kura Oncology. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.

New publication 📝 Phase III E2906 results, published in @BloodPortfolio, show clofarabine did not lower 30-day induction mortality or improve survival vs 7+3 chemotherapy in fit older adults with ND #AML. Learn more: bit.ly/4d7gctS #AMLsm #leusm #MedNews #MedEd

New publication 📝 A retrospective comparison, published in @BloodCancerJnl, shows similar CR/CRi rates (55% vs 60%) with CPX‑351 vs Ven + HMA in ND #AML, including in the AML‑MR subgroup (60% vs 63%). Transplant-censored EFS favored Ven + HMA. Learn more: bit.ly/3NSE3Vk #AMLsm #leusm #MedNews #MedEd

🎥 The AML Hub was pleased to speak with Dr Joshua Zeidner. He provided an overview of key insights emerging from ongoing trials of menin inhibitor combination strategies for the treatment of AML. Watch the full video here: bit.ly/48nZNQh #AMLsm #leusm #MedEd @LeukDocJZ Intended for healthcare professionals only. This educational resource is independently supported by Kura Oncology. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.

🎥 The AML Hub was pleased to speak with Dr Gail Roboz. She provided an overview of the potential side effects of menin inhibitor-based regimens for the treatment of AML, and how she manages them in clinical practice. Watch the full video here: bit.ly/4cH8mXM #AMLsm #leusm #MedEd Intended for healthcare professionals only. Independently supported by Kura Oncology. Funders were allowed no influence.

🎥 The AML Hub was pleased to speak with Eunice Wang. She provided an overview of why menin inhibitor combination strategies may improve outcomes in the treatment of NPM1m or KMT2Ar AML. Watch the full video here: bit.ly/41MjjlT #AMLsm #leusm #MedEd @EuniceWangMD Intended for healthcare professionals only. This educational resource is independently supported by Kura Oncology. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.

New publication 📝Results from a retrospective cohort study, published in @Haematologica, show HMA + Ven yields comparable post-allo‑HSCT OS vs IC in older patients with adverse-risk AML (34.4 vs 28.3 months; p = 0.636). Learn more: bit.ly/4w0mtA7 #AML #leusm #MedNews #MedEd

🎥 The AML Hub was pleased to speak with Dr Joshua Zeidner. We asked, What key insights are emerging from ongoing trials of menin inhibitor combination strategies in AML? Watch the full video here: bit.ly/48nZNQh #AMLsm #leusm #MedEd @LeukDocJZ Intended for healthcare professionals only. This educational resource is independently supported by Kura Oncology. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.

🎥 The AML Hub Steering Committee, led by Jorge Cortes, recently discussed the topic: Menin inhibitors in AML: Where are we now, and where are we going? Watch the video here: bit.ly/4crSucK #AMLsm #leusm #MedEd @charliecraddock @jorgecortesmd @LancetJeff Intended for healthcare professionals only. This educational resource is independently supported by Johnson & Johnson. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.

🎥 The AML Hub was pleased to speak with Dr Gail Roboz. We asked, What side effects are typically observed with menin inhibitor-based regimens, and how do you approach managing them in clinical practice? Watch the full video here: bit.ly/4cH8mXM #AMLsm #leusm #MedEd Intended for healthcare professionals only. Independently supported by Kura Oncology. Funders were allowed no influence.

🎥 The AML Hub recently discussed the topic of personalized treatment decisions in FLT3-mutated AML, led by Jorge Sierra. Watch the video here: bit.ly/4sKeLHv #AMLsm #leusm #MedEd @charliecraddock @jorgecortesmd @LancetJeff @UwePlatzbecker @RolandBWalter Intended for healthcare professionals only. This educational resource is independently supported by Daiichi Sankyo. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.

🎥 The AML Hub was pleased to speak with Eunice Wang. We asked, What are the mechanisms and rationale for menin inhibitor combination strategies for the treatment of AML? Watch the full video here: bit.ly/41MjjlT #AMLsm #leusm #MedEd @EuniceWangMD Intended for healthcare professionals only. This educational resource is independently supported by Kura Oncology. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.

🎥 During the recent AML Hub Steering Committee meeting, Jorge Cortes chaired a discussion on the current status and future directions of menin inhibition in the treatment of AML. Watch the video here: bit.ly/4crSucK #AMLsm #leusm #MedEd @charliecraddock @jorgecortesmd @LancetJeff Intended for healthcare professionals only. This educational resource is independently supported by Johnson & Johnson. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.

New publication 📝 Results from an exploratory analysis of the phase III QuANTUM-First trial, published in @BloodPortfolio, show quizartinib maintenance was associated with prolonged OS and RFS vs placebo in ND FLT3-ITD #AML, with a pronounced benefit in non-transplanted and MRD-negative patients. Learn more: bit.ly/4cK7Ael #AMLsm #leusm #MedNews #MedEd

New publication 📝 Results from a prospective pilot study, published in @BrJHaem, show reduced-dose post-transplant cyclophosphamide was associated with faster platelet engraftment (13 vs 16 days; p < 0.001) in adults with AML undergoing MUD allo-HSCT. Learn more: bit.ly/4tj1Wp3 #AMLsm #leusm #MedNews #MedEd

📝 Using our downloadable journal can be an incredible way to reflect on your personal journey with AML. If you feel comfortable, please share them with us using the hashtags #KnowAML and #AMLWorldAwarenessDay bit.ly/4sPGdUT #Cancer #Leukemia #Leucemia